Imara
company
About
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
- 1 - 10
Details
- Last Funding Type
- Seed
- Last Funding Money Raised
- $800K
- Industries
- Biopharma,Biotechnology,Genetics,Health Care,Therapeutics
- Founded date
- Jan 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$800K
Imara has raised a total of
$800K
in funding over 2 rounds. Their latest funding was raised on
Jan 1, 2016 from a Seed round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 1, 2016 | Seed | $800K | 1 | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
